2024 Diagnostics Research Review

Description

List of Tables

The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.

The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 and is projected to reach $15.4 billion by 2028, at a CAGR of 15.2% from 2023 through 2028.

The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a CAGR of 7.6% during the forecast period of 2024 to 2029.

Research Review Scope

The diagnostics industry has grown despite the challenging economic conditions in recent years. The industry draws much attention and scrutiny from the public and government and is currently undergoing many changes due to increased focus on regulations. These changes can be seen across many countries. The U.S., the largest diagnostics market, is leading the trend with changes intended to make healthcare more affordable. Opportunities for the diagnostics industry are manifold with the appearance of new markets located mainly in emerging economies with varying needs.

Increasing healthcare expenditures and the growth of emerging economies have increased the demand for technologically better diagnostic devices, kits, reagents, and other accessories. Additionally, the introduction of more stringent regulations, specifically in the developed markets of the U.S. and Europe, has forced diagnostics manufacturers to launch advanced products that include new materials, a focus on in-depth indications, and the ability to produce additional new data.

Some of the major driving factors in the market are increasing prevelance of chronic and infectious diseases, technological advancements in the diagnostics, increasing investments in AI in diagnostics market, increased applications in non-oncology areas, growing adotion of personalized medicine, and other driving factors.

Furthermore, technically sophisticated diagnostics are needed for clinical research, as the market is highly competitive, and companies must continuously reinvent their product portfolios to enter new markets and place themselves as significant players in the healthcare system. There is a shift toward a value-based healthcare market where price and purchase decisions are based on outcomes. This has further resulted in increased scrutiny of the technology of devices, and consequently, the degree of competition has risen. Some of the major players in the diagnostics market include Abbott, Medtronic, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, GE Healthcare, Koninklijke Philips N.V., Agilent Technologies Inc., QIAGEN, Danaher Corp., Sysmex, Thermo Fisher Scientific, Inc., BD, and others.

The diagnostics industry is a multi-billion-dollar market whose outlook is supposed to rise in the coming years. Hospital care is growing, and the diagnostics industry is being looked at to provide low-cost technology for home healthcare. Now, the industry seeks healthcare diagnostic devices, kits, and reagents that individuals with unskilled healthcare experience can use. The need for modern technology, equipment, and devices can be leveraged through diagnostic equipment as manufacturers seek to create better-quality healthcare solutions.

Today's market is worthy of close investigation as it deals with the fallout from COVID-19 and how the global diagnostics market is after the post-COVID-19 pandemic. The global pandemic has impacted the diagnostics industry both positively and negatively.

The above reasons are compelling enough to analyze and research the diagnostics market, as the market has tremendous growth potential.

It includes highlights from these reports published in 2024:

BIO261A AI in Clinical and Molecular Diagnostics Market
BIO077F Companion Diagnostics: Technologies and Global Markets
PHM116C Drugs and Diagnostics for Hematological Disorders Global Markets
BIO233B In Vitro Diagnostics (IVD) Quality Controls: Global Market
HLC043H Point of Care Diagnostics: Technologies and Global Markets
BIO157C Polymerase Chain Reaction (PCR) for Point of Care (POC) Diagnostics
PHM227B Rare Disease Diagnostics: Technologies and Global Markets

After you survey the excerpts in this Research Review, we encourage you to follow up on these topics by checking out the full market research reports associated with each topic. BCC Research looks forward to serving your market intelligence needs in the future.

Product Code: BIO263A

Chapter 1 Foreword

Research Review Scope

Chapter 2 AI in Clinical and Molecular Diagnostics Market(BIO261A)

AI in Clinical and Molecular Diagnostics
Market Outlook
Scope of Report
Market Summary
Market Overview of AI in Clinical and Molecular Diagnostics
AI in Healthcare
AI in Clinical Diagnostics
AI in Molecular Diagnostics
Market Dynamics of AI in Clinical and Molecular Diagnostics
Market Drivers
Investment in the AI Health Sector
Increasing Prevalence of Chronic and Infectious Diseases
Technological Advances
Demand for Personalized Medicine
Market Restraints
Practitioners Reluctant to Adopt AI-based Technologies
Data Security
Regulatory Challenges
Market Opportunities
Software with AI
Untapped Opportunities in Developing Markets
Regulatory Structure
Emerging Technologies and Developments
Machine Learning Algorithms
Deep Learning
Generative AI
Natural Language Processing (NLP)
Genomic AI
Cloud-Based Solutions
Market Segmentation Analysis
AI in Clinical and Molecular Diagnostics: Global Markets
Molecular Diagnostics
Clinical Diagnostics
Market Analysis of AI in Clinical and Molecular Diagnostics by Component
Software
Services
Hardware
Geographic Breakdown
Market Analysis 0f AI in Clinical and Molecular Diagnostics by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 3 Companion Diagnostics: Technologies and Markets ( BIO077F)

Companion Diagnostics
Market Outlook
Scope of Report
Market Summary
Highlights of the Market for Companion Diagnostics (CDx)
Market Introduction
Regulatory Landscape
Companion Diagnostics Regulations in the U.S.
Companion Diagnostics Regulations Outside the U.S.
LDT-CDx Regulation
Market Dynamics of Companion Diagnostics
Market Drivers
Rising Incidence of Cancer
Growing Adoption of Personalized Medicine
Expanded Application in Non-Oncology Areas
Optimization of Drug Development Costs
Market Restraints
High Development Cost of CDx
Reimbursement Challenges
Market Opportunities
Advances in NGS Technologies
Market Challenges
Inefficiencies in Clinical Testing Landscape
Lack of Skilled Labor
Emerging Technologies and Developments
Multiplex Testing
Next-Generation Sequencing (NGS)
Digital PCR
Liquid Biopsy
Artificial Intelligence
Market Segmentation Analysis
Global Market for Companion Diagnostics by Product and Service
Market Share and Forecast
Instruments
Consumables
Services
Global Market for Companion Diagnostics by Type of Test
Market Share and Forecast
LDT-CDx
Commercial CDx
Global Market for Companion Diagnostics by Technology
Market Share and Forecast
Polymerase Chain Reaction
Immunohistochemistry
Next-Generation Sequencing
In Situ Hybridization
Genotyping
Immunoassays
Exosomes
Others
Services
Global Market for Companion Diagnostics by Application
Market Share and Forecast
Cancer
Market for the Application of CDx in Cancer by Type
Neurologic Disorders
Cardiovascular Disease
Infectious Diseases
Other Diseases
Market Breakdown of Companion Diagnostics by End User
Market Share and Forecast
Clinical Laboratories
Pharmaceutical Companies
Contract Research Organizations (CROs)
Other End Users
Geographic Breakdown
Global Market for Companion Diagnostics by Region
North America
The U.S.
Canada
Europe
Germany
The U.K.
France
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Rest of the World

Chapter 4 Drugs and Diagnostics for Hematological Disorders: Global Markets (PHM116C)

Drugs and Diagnostics for Hematological Disorders
Market Outlook
Scope of Report
Market Summary
Market Overview of Drugs and Diagnostics for Hematological Disorders
PESTEL Analysis
Political
Economic
Social
Technological
Environmental
Legal
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential of New Entrants
Threat of Substitutes
Competition in the Industry
Supply Chain and Logistics for Hematological Instruments
Market Dynamics of Drugs and Diagnostics for Hematological Disorders
Market Drivers
Incidence of Blood Disorders
Rising Use of Automation
Diagnosis of Hematology Disorders
Increasing Government and Private Funding for Treatment
Market Restraints
High Cost of Instruments
High Cost of Treatment
Reimbursement Challenges for Physicians
Market Opportunities
Rising Health Awareness
Emerging Economies
Emerging Technologies and Developments
AI-Assisted Diagnosis
Next-Generation Sequencing (NGS)
Microfluidics and Lab-on-a-Chip Devices
Gene Therapies
Immunotherapies
Market Segmentation Analysis
Segmentation by Market
Hematological Disorders Diagnostics Market
Hematological Disorders Diagnostic Market, By Product Type
Hematological Disorders Diagnostic Market, By End User
Hematology Drug Market
Hematology Drug Market, By Drug Type
Geographic Breakdown
North America
Europe
Asia-Pacific
Rest of the World

Chapter 5 In Vitro Diagnostics (IVD) Quality Controls: Global Market( BIO233B)

In Vitro Diagnostics (IVD) Quality Controls
Market Outlook
Scope of Report
Market Summary
Market and Technology Background
Overview
Classification of In Vitro Diagnostics Elements
Importance of In Vitro Diagnostics Quality Control
Regulations
Regulation of IVD products in Different countries
Market Dynamics of In Vitro Diagnostics (IVD) Quality Controls
Market Drivers
Rise in the Aging Population and Dependency on Frequent Diagnosis Procedures
Rising Demand for Third-Party Quality Control Products
Rising Incidence of Chronic Disease Cases
Strengthening Clinical Laboratories
Improving the Quality of Point-of-Care Testing
Market Restraints
Challenges for Quality Control Product Packaging
Increases in Shipping Costs or Service Issues
Improper Operation and Maintenance of Laboratory Equipment and Consumables
Market Opportunities
Rise in Home Care Testing Devices
Demand for Point-of-Care (POC) Testing Units
Emerging Technologies and Developments
Artificial Intelligence
Prioritizing Old IVD Techniques
Automating In-Vitro Diagnostic Devices
Emerging Trends in In Vitro Diagnostics
FDA Approval
Rise in Demand for Personalized Medicine
Market Segmentation Analysis
Market Breakdown of In Vitro Diagnostics (IVD) Quality Controls by Test Type
Immunodiagnostics
Clinical Chemistry
Hematology
Molecular Diagnostics
Microbiology
Other Test Types
Market Breakdown of In Vitro Diagnostics (IVD) Quality Controls by Type of Manufacturer
Third-party Controls
ODM Controls
Market Breakdown of In Vitro Diagnostics (IVD) Quality Controls by Products and Services
Quality Control Products
Data Management Solutions
Quality Assurance Services
Market Breakdown of In Vitro Diagnostics (IVD) Quality Controls by End User
Diagnostic Laboratories
Hospitals and Clinics
Point-of-Care Centers
Research Institutions
Other End Users
Geographic Breakdown
Market Analysis of In Vitro Diagnostics (IVD) Quality Controls by Region
North America
Market Size and Forecast
U.S.
Canada
Mexico
Europe
Market Size and Forecast
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Market Size and Forecast
Japan
China
India
Australia and New Zealand
Rest of Asia-Pacific
Rest of the World
Market Size and Forecast
Brazil
GCC Countries
Rest of the World Countries

Chapter 6 Point-of-Care Diagnostics: Technologies and Global Markets ( HLC043H)

Point-of-Care Diagnostics
Market Outlook
Scope of Report
Market Summary
Market Overview of Point-of-Care Diagnostics
Novel Approaches for POC
Significance of CLIA in the United States
Regulatory Guidelines
Good Manufacturing Practice
The FDA's Role in POC Testing
Conclusion
Market Dynamics of Point-of-Care Diagnostics
Market Drivers
High Incidences of Infectious Diseases
Growing Prevalence of Chronic Diseases
Increasing Demand for Self-Testing
Aging Population
Market Restraints
Challenges Faced by POC Manufacturers Due to Pricing Pressure
Technical Complexity
Lack of Specialized Training
Market Challenges
Challenges in Deploying Point-of-Care (POC) Diagnostics in Remote Settings
Environmental and Contamination Challenges in Point-of-Care Diagnostics
Market Opportunities
Increasing R&D Budget
Excellent Market Potential for POCT with AI and ML Integration
Emerging Economies
Emerging and Upcoming Technologies in the Market
AI in Point-of-Care Diagnostics
CRISPR-Cas Systems
3D Rapid Prototyping
Quantum Dots
RFID (Radio-Frequency Identification) and NFC (Near Field Communication)
Smartphone-Based Medical Imaging
Nanomaterials in POC Devices for Pathogen Detection
Microfluidics-Based Sensing Technologies
Cloud-Integrated AI
D3 Array-UTI
EVIK DxSpheres: A Solid Assay Solution
UNIQO 160 Automated IIFT System

Recent Developments

Market Segmentation Analysis
Market Breakdown of Point-of-Care Diagnostics by Test Type
Drug and Alcohol Screening
Blood Gas Electrolyte and Metabolite (BGEM)
Cardiac Markers
Cholesterol Testing/Monitoring
Glucose Testing and Monitoring
Infectious Disease Testing
Pregnancy and Fertility Testing
Hemoglobin and Hemostasis
Tumor Marker
Urinalysis/Urine Chemistry
Others
Market Breakdown of Point-of-Care Diagnostics Market by Product
Hardware
Software
Market Breakdown of Point-of-Care Diagnostics Market by End User
Hospitals and Critical Care Settings
Home Care Settings
Geographic Breakdown
Market Breakdown of Point-of-Care Diagnostics Market by Region
North America
Europe
Asia-Pacific
Rest of the World (RoW)

Chapter 7 Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics (BIO157C)

Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics
Market Outlook
Scope of Report
Market Summary
Market Overview of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics
Polymerase Chain Reaction Technology
Point of Care PCR Systems and Assays
Market Dynamics of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics
Market Drivers
Increasing Incidence of Infectious Diseases
Decentralization of Testing
Increasing Adoption of Point-of-Care Testing and Expansion
Multiplexing Testing
Response to the Pandemics
Market Opportunities
Integration of PCR POC Technology in Primary Care and Low-Income Countries
Market Restraints
High Initial Cost
Market Competition
Market Challenges
Operational Challenges
Supply Shortages
Emerging Technologies and Developments
Instrument-Free PCR Tests
Five-Minute Point-of-Care Testing
Smartphone Enabled PCR System
Global Market for PCR POC Diagnostics
Market Breakdown of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics by Product Type
Market Breakdown of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics by Analyte
PCR POC Analyzers by Analyte
PCR POC Consumables by Analyte
Market Breakdown of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics by Application
Infectious Diseases
STIs
Geographic Breakdown
Market Breakdown of Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics by Region
North America
Latin America
Europe
Asia-Pacific
Rest of the World

Chapter 8 Rare Disease Diagnostics: Technologies and Global Markets (PHM227B)

Rare Disease Diagnostics
Market Outlook
Scope of Report
Market Summary
Market Overview of Rare Disease Diagnostics
Diagnostic Odyssey
What Is Genomic Testing?
Rare Disease Clinical Assays Development and Marketing
Rare Disease Treatment
Bioinformatic Resources for Rare Disease Research and Genetic Information
Large-Scale Initiatives and Consortia
Population Sequencing Programs
Market Dynamics of Rare Disease Diagnostics
Market Drivers
Significant Unmet Need in Rare Disease Diagnostics
Orphan Drug Act
Advances In Gene Therapy
Rare Disease Initiatives
Advances in Genomic Technologies and Analytical Tools
Decreasing Cost of Next-Generation Sequencing (NGS)
Market Driving Forces and Their Impact on Market Growth
Market Restraints
Lack of Commercially Available IVDs for Rare Disease Diagnosis
Stringent Regulatory Landscape
Ethical and Legal Concerns
Shortage of Genetic and Rare Disease Specialists
Emerging Technologies and Developments
Shift Towards a Multi-omics Approach
Artificial Intelligence (AI) and Machine Learning
Collaboration Between Rare Disease Diagnostics and Pharma Companies
Market Segmentation Analysis
Market Breakdown of Rare Disease Diagnostics by Analysis Platform
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Sanger Sequencing
Microarrays
Karyotyping and Fluorescent in Situ Hybridization (FISH)
Biochemical Testing
Market Breakdown of Rare Disease Diagnostics by Analysis Target Type
Single Genes
Multiple Genes
Whole Exome
Whole Genome
Other Genomic Variants
Protein and Other Biochemical Markers
Market Breakdown of Rare Disease Diagnostics by Disease Class
Rare Cancers
Neurological Diseases
Metabolic and Endocrine Disorders
Hematology
Respiratory
Immune System and Inflammation-Related Disorders
Dermatology
Musculoskeletal
Others
Market Breakdown of Rare Disease Diagnostics by Test Purpose
Diagnosis
Screening and Early Detection
Therapy Guidance
Monitoring
Geographic Breakdown
Market Breakdown of Rare Disease Diagnostics by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 9 Appendix

Methodology
Analyst's Credentials

Product Code: BIO263A

List of Tables

Table 1 : Global Market for AI in Clinical and Molecular Diagnostics, by Type, Through 2029
Table 2 : Global Market for AI in Clinical and Molecular Diagnostics, by Region, Through 2029
Table 3 : Regulations Pertaining to AI Medical Diagnostics
Table 4 : Global Market for AI in Clinical and Molecular Diagnostics, Through 2029
Table 5 : Global Market for AI in Clinical and Molecular Diagnostics, by Type, Through 2029
Table 6 : Global Market for AI in Molecular Diagnostics, by Application, Through 2029
Table 7 : Incidence of Cancer, by Region, 2022
Table 8 : Number of DALYs for Neurological Disorders and Share of Global DALYs Projected for 2005 and 2030
Table 9 : Global Market for AI in Molecular Diagnostics, by Product Type, Through 2029
Table 10 : Global Market for AI in Clinical Diagnostics, by Test, Through 2029
Table 11 : Global Market for AI in Clinical Diagnostics, by Product, Through 2029
Table 12 : Global Market for AI in Clinical and Molecular Diagnostics, by Component, Through 2029
Table 13 : Global Market for AI in Clinical and Molecular Diagnostics, by Region, Through 2029
Table 14 : North American Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029
Table 15 : European Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029
Table 16 : Asia-Pacific Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029
Table 17 : RoW Market for AI in Clinical and Molecular Diagnostics, by Sub-Region, Through 2029
Table 18 : Global Market for Companion Diagnostics, by Product, Through 2028
Table 19 : Global Market for Companion Diagnostics, by Region, Through 2028
Table 20 : Expanded/New CDx Testing for Personalized Medicine in 2022
Table 21 : Global Market for Companion Diagnostics, by Product and Service, Through 2028
Table 22 : Companion Diagnostics Instruments
Table 23 : Global Market for Companion Diagnostics Instruments, by Region, Through 2028
Table 24 : Global Market for Companion Diagnostics Consumables, by Region, Through 2028
Table 25 : Global Market for Companion Diagnostics Services, by Region, Through 2028
Table 26 : Global Market for Companion Diagnostics, by Type of Test, Through 2028
Table 27 : Global Market for Laboratory Developed Test (LDT)-CDx, by Region, Through 2028
Table 28 : List of FDA-Approved Companion Diagnostics, by Company, as of December 2023
Table 29 : Global Market for Commercial-CDx, by Region, Through 2028
Table 30 : FDA-Approved CDx Tests, by Technology, as of December 2023
Table 31 : Global Market for Companion Diagnostics, by Technology, Through 2028
Table 32 : List of FDA-Approved PCR-CDx, by Company, as of December 2023
Table 33 : Global Market for Polymerase Chain Reaction CDx, by Region, Through 2028
Table 34 : Global Market for Polymerase Chain Reaction CDx, by Application, Through 2028
Table 35 : List of FDA-Approved IHC-CDx, by Company, as of December 2023
Table 36 : Global Market for Immunohistochemistry CDx, by Region, Through 2028
Table 37 : Global Market for Immunohistochemistry CDx, by Application, Through 2028
Table 38 : List of FDA-Approved NGS-CDx, by Company, as of December 2023
Table 39 : Global Market for Next-Generation Sequencing CDx, by Region, Through 2028
Table 40 : Global Market for Next-Generation Sequencing CDx, by Application, Through 2028
Table 41 : Global Market for In Situ Hybridization CDx, by Region, Through 2028
Table 42 : Global Market for In Situ Hybridization CDx, by Application, Through 2028
Table 43 : Global Market for Genotyping CDx, by Region, Through 2028
Table 44 : Global Market for Genotyping CDx, by Application, Through 2028
Table 45 : Global Market for Immunoassays CDx, by Region, Through 2028
Table 46 : Global Market for Immunoassays CDx, by Application, Through 2028
Table 47 : Global Market for Exosome CDx, by Region, Through 2028
Table 48 : Global Market for Exosomes CDx, by Application, Through 2028
Table 49 : Global Market for Other CDx, by Region, Through 2028
Table 50 : Global Market for Other CDx, by Application, Through 2028
Table 51 : Technological Expertise in the CDx Services Sector
Table 52 : Global Market for CDx Services, by Region, Through 2028
Table 53 : Global Market for CDx Services, by Application, Through 2028
Table 54 : Global Market for Companion Diagnostics, by Application, Through 2028
Table 55 : Global Market for Companion Diagnostics in Cancer Applications, by Region, Through 2028
Table 56 : Cancer Incidence, Global, by Cancer Type, 2022
Table 57 : Approved CDx Drugs for Cancer Treatment, by Cancer Type, 2023
Table 58 : Global Market for Companion Diagnostics in Cancer Applications, by Cancer Type, Through 2028
Table 59 : Global Market for Companion Diagnostics in Neurologic Disorder Applications, by Region, Through 2028
Table 60 : Global Market for Companion Diagnostics in Neurologic Disorder Applications, by Type, Through 2028
Table 61 : Global Market for Companion Diagnostics in Cardiovascular Disease Applications, by Region, Through 2028
Table 62 : Global Market for Companion Diagnostics in Infectious Disease Applications, by Region, Through 2028
Table 63 : Global Market for Companion Diagnostics in Other Disease Applications, by Region, Through 2028
Table 64 : Global Market for Companion Diagnostics, by End User, Through 2028
Table 65 : Global Market for Companion Diagnostics in Clinical Laboratories, by Region, Through 2028
Table 66 : Recent Collaborations and Partnerships in the Companion Diagnostics Market, 2022 and 2023
Table 67 : Global Market for Companion Diagnostics in Pharmaceutical Companies, by Region, Through 2028
Table 68 : Global Market for Companion Diagnostics in Contract Research Organizations, by Region, Through 2028
Table 69 : Global Market for Companion Diagnostics in Other End Users, by Region, Through 2028
Table 70 : Global Market for Companion Diagnostics, by Region, Through 2028
Table 71 : North American Market for Companion Diagnostics, by Country, Through 2028
Table 72 : European Market for Companion Diagnostics, by Country, Through 2028
Table 73 : Asia-Pacific Market for Companion Diagnostics, by Country, Through 2028
Table 74 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029
Table 75 : Blood-Related Disorders
Table 76 : Incidence of Blood Cancer Types in U.S., 2023
Table 77 : Total Cost of Care for CLL Patients Treated in the U.S., 2023
Table 78 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 79 : Global Market for Diagnostics for Hematological Disorders, by Region, Through 2029
Table 80 : Global Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 81 : Global Market for Hematology Instruments and Software, by Region, Through 2029
Table 82 : Global Market for Hematology Reagents, by Region, Through 2029
Table 83 : Global Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 84 : Global Market for Hematology Diagnosis in Diagnostic Centers, by Region, Through 2029
Table 85 : Global Market for Hematology Diagnosis in Hospitals and Clinics, by Region, Through 2029
Table 86 : Global Market for Hematology Diagnosis in Other End Users, by Region, Through 2029
Table 87 : Global Market for Hematology Drugs, by Region, Through 2029
Table 88 : Global Market for Hematology Drugs, by Drug Type, Through 2029
Table 89 : Drugs Approved for Hematologic Cancers
Table 90 : Global Market for Hematology Oncology Drugs, by Region, Through 2029
Table 91 : Global Market for Hematology Non-Oncology Drugs, by Region, Through 2029
Table 92 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029
Table 93 : North American Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
Table 94 : North American Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 95 : North American Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 96 : North American Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 97 : North American Market for Hematology Drugs, by Drug Type, Through 2029
Table 98 : European Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
Table 99 : European Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 100 : European Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 101 : European Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 102 : European Market for Hematology Drugs, by Drug Type, Through 2029
Table 103 : Incidence of Blood-Related Cancers, by Country, 2022
Table 104 : Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
Table 105 : Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 106 : Asia-Pacific Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 107 : Asia-Pacific Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 108 : Asia-Pacific Market for Hematology Drugs, by Drug Type, Through 2029
Table 109 : Asia-Pacific Incidence of Blood-Related Cancers, by Country, 2022
Table 110 : RoW Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
Table 111 : RoW Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
Table 112 : RoW Market for Diagnostics for Hematological Disorders, by End User, Through 2029
Table 113 : RoW Market for Hematology Drugs, by Drug Type, Through 2029
Table 114 : Global Market for In Vitro Diagnostics Quality Controls, by Test Type, Through 2029
Table 115 : Global Market for In Vitro Diagnostics Quality Controls, by Test Type, Through 2029
Table 116 : Global Market for Immunodiagnostics, by Region, Through 2029
Table 117 : Global Market for Clinical Chemistry, by Region, Through 2029
Table 118 : Global Market for Hematology, by Region, Through 2029
Table 119 : Global Market for Molecular Diagnostics, by Region, Through 2029
Table 120 : Global Market for Microbiology, by Region, Through 2029
Table 121 : Global Market for Other Test Types, by Region, Through 2029
Table 122 : Global Market for In Vitro Diagnostics Quality Controls, by Type of Manufacturer, Through 2029
Table 123 : Global Market for Third-party Controls, by Region, Through 2029
Table 124 : Global Market for ODM Controls, by Region, Through 2029
Table 125 : Global Market for In Vitro Diagnostics Quality Controls, by Type of Product and Service, Through 2029
Table 126 : Global Market for Quality Control Products, by Region, Through 2029
Table 127 : Global Market for Serum/Plasma-Based Controls, by Region, Through 2029
Table 128 : Global Market for Whole Blood-Based Controls, by Region, Through 2029
Table 129 : Global Market for Urine-based Controls, by Region, Through 2029
Table 130 : Global Market for Other Quality Control Products, by Region, Through 2029
Table 131 : Global Market for Data Management Solutions, by Region, Through 2029
Table 132 : Global Market for Quality Assurance Services, by Region, Through 2029
Table 133 : Global Market for In Vitro Diagnostics Quality Controls, by End User, Through 2029
Table 134 : Global Market for IVD Quality Controls in Diagnostic Laboratories, by Region, Through 2029
Table 135 : Global Market for IVD Quality Controls in Hospitals and Clinics, by Region, Through 2029
Table 136 : Global Market for IVD Quality Controls in Point-of-Care Centers, by Region, Through 2029
Table 137 : Global Market for IVD Quality Controls in Research Institutions, by Region, Through 2029
Table 138 : Global Market for Other End Users, by Region, Through 2029
Table 139 : Global Market for In Vitro Diagnostics Quality Controls, by Region, Through 2029
Table 140 : North American Market for In Vitro Diagnostics Quality Controls, by Country, Through 2029
Table 141 : European Market for In Vitro Diagnostics Quality Controls, by Country, Through 2029
Table 142 : Asia-Pacific Market for In Vitro Diagnostics Quality Controls, by Country, Through 2029
Table 143 : Rest of the World Market for In Vitro Diagnostics Quality Controls, by Country/Sub-Region, Through 2029
Table 144 : Global Market for Point-of-Care Diagnostics, by Region, Through 2029
Table 145 : POCT Alternatative Terms
Table 146 : Commonly Used POC Devices
Table 147 : Recent Tests Approved by the FDA as Waived Tests Under CLIA
Table 148 : Estimated Number of People Living with HIV, 2010, 2021 and 2022
Table 149 : Number of Hepatitis B Infections (All Ages) in 2022
Table 150 : Global Incidences of STIs, 2020 and 2022
Table 151 : Projected Number of Adults 50 Years and Older with >=1 Chronic Condition in the United States, 2020-2050
Table 152 : Number and Proportion of Persons Aged 65 Years and Over, by Development Group, 2023 and 2050
Table 153 : Number of Persons Aged 65 Years and Over, by Region, 2019 and 2050
Table 154 : Number of Deaths and the Age-Adjusted Death Rate for the 10 Leading Causes of Death in 2022: United States, 2021 and 2022
Table 155 : Global Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 156 : Global Market for Drug and Alcohol Screening, by Region, Through 2029
Table 157 : Global Market for BGEM, by Region, Through 2029
Table 158 : Global Market for Cardiac Markers, by Region, Through 2029
Table 159 : Global Market for Cholesterol Testing/Monitoring, by Region, Through 2029
Table 160 : Global Market for Glucose Testing and Monitoring, by Region, Through 2029
Table 161 : Annual Estimated Deaths from HIV/AIDS, Diarrhea, Malaria, Respiratory Infections, and All Other Infectious Diseases in Major Countries, 1980 to 2021
Table 162 : Global Market for Infectious Disease Testing, by Region, Through 2029
Table 163 : Global Market for Pregnancy and Fertility Testing, by Region, Through 2029
Table 164 : Global Market for Hemoglobin and Hemostasis, by Region, Through 2029
Table 165 : Examples of Commercially Available POC Devices for Cancer Detection
Table 166 : Global Market for Tumor Markers, by Region, Through 2029
Table 167 : Some Currently Available Point-of-Care Tests for Proteins in Urine
Table 168 : Global Market for Urinalysis/Urine Chemistry, by Region, Through 2029
Table 169 : Global Market for Other Types of Point-of-Care Diagnostics Tests, by Region, Through 2029
Table 170 : Global Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 171 : Global Market for Hardware in Point-of-Care Diagnostics, by Region, Through 2029
Table 172 : Global Market for Software in Point-of-Care Diagnostics, by Region, Through 2029
Table 173 : Global Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 174 : Global Market for Point-of-Care Diagnostics in Hospital and Critical Care End Uses, by Region, Through 2029
Table 175 : Global Market for Point-of-Care Diagnostics in Home Care Settings, by Region, Through 2029
Table 176 : Global Market for Point-of-Care Diagnostics, by Region, Through 2029
Table 177 : North American Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 178 : North American Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 179 : North American Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 180 : North American Market for Point-of-Care Diagnostics, by Country, Through 2029
Table 181 : U.S. Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 182 : U.S. Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 183 : U.S. Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 184 : Canadian Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 185 : Canadian Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 186 : Canadian Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 187 : Mexican Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 188 : Mexican Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 189 : Mexican Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 190 : European Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 191 : European Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 192 : European Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 193 : European Market for Point-of-Care Diagnostics, by Country, Through 2029
Table 194 : Leading Causes of Disease Burden by DALYs (Level 3)
Table 195 : German Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 196 : German Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 197 : German Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 198 : U.K. Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 199 : U.K. Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 200 : U.K. Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 201 : French Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 202 : French Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 203 : French Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 204 : Italian Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 205 : Italian Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 206 : Italian Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 207 : Spanish Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 208 : Spanish Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 209 : Spanish Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 210 : Rest of European Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 211 : Rest of European Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 212 : Rest of European Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 213 : Asia-Pacific Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 214 : Asia-Pacific Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 215 : Asia-Pacific Market for Point-of-Care Diagnostics, by End User Through 2029
Table 216 : Asia-Pacific Market for Point-of-Care Diagnostics, by Country, Through 2029
Table 217 : Chinese Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 218 : Chinese Market for Point-of-Care Diagnostics, by Product, Through 2029Chinese Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 219 : Chinese Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 220 : Japanese Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 221 : Japanese Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 222 : Japanese Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 223 : Indian Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 224 : Indian Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 225 : Indian Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 226 : Australian Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 227 : Australian Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 228 : Australian Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 229 : South Korean Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 230 : South Korean Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 231 : South Korean Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 232 : Rest of Asia-Pacific Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 233 : Rest of Asia-Pacific Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 234 : Rest of Asia-Pacific Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 235 : Rest of the World Market for Point-of-Care Diagnostics, by Test Type, Through 2029
Table 236 : Rest of the World Market for Point-of-Care Diagnostics, by Product, Through 2029
Table 237 : Rest of the World Market for Point-of-Care Diagnostics, by End User, Through 2029
Table 238 : Global Market for Polymerase Chain Reaction for Point-of-Care Diagnostics, by Product Type, Through 2029
Table 239 : Global HIV Infections, 2022
Table 240 : People Living with HIV, by Region, 2022
Table 241 : Global Incidence of All Cancers, by Region, 2022-2050
Table 242 : Global Incidence of Leukemia, by Region, 2022-2050
Table 243 : Global Incidence of Hodgkin Lymphoma, by Region, 2022-2050
Table 244 : Global Incidence of Non-Hodgkin Lymphoma, by Region, 2022-2050
Table 245 : Global Incidence of Multiple Myeloma, by Region, 2022-2050
Table 246 : Global Market for PCR POC Diagnostics, Through 2029
Table 247 : Global Market for PCR POC Diagnostics, by Product Type, Through 2029
Table 248 : Global Market for PCR POC Analyzers, by Analyte, Through 2029
Table 249 : Global Market for Single Analyte PCR POC Analyzers, by Region, Through 2029
Table 250 : Global Market for Multi-Analyte PCR POC Analyzers, by Region, Through 2029
Table 251 : Global Market for PCR POC Consumables, by Analyte, Through 2029
Table 252 : Global Market for Single Analyte PCR POC Consumables, by Region, Through 2029
Table 253 : Global Market for Multi-Analyte PCR POC Consumables, by Region, Through 2029
Table 254 : Global Market for PCR for POC Diagnostics, by Application, Through 2029
Table 255 : Global Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
Table 256 : Global Market for PCR POC Diagnostics in Infectious Diseases, by Region, Through 2029
Table 257 : North American Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
Table 258 : North American Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029
Table 259 : Latin American Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
Table 260 : Latin American Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029
Table 261 : European Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
Table 262 : European Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029
Table 263 : Asia-Pacific Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
Table 264 : Asia-Pacific Market for PCR POC Diagnostics in Infectious Diseases, by Country, Through 2029
Table 265 : RoW Market for PCR POC Diagnostics in Infectious Diseases, Through 2029
Table 266 : Global Market for PCR POC Diagnostics in STIs, Through 2029
Table 267 : Global Market for PCR POC Diagnostics in STIs, by Region, Through 2029
Table 268 : North American Market for PCR POC Diagnostics in STIs, Through 2029
Table 269 : North American Market for PCR POC Diagnostics in STIs, by Country, Through 2029
Table 270 : Latin American Market for PCR POC Diagnostics in STIs, Through 2029
Table 271 : Latin American Market for PCR POC Diagnostics in STIs, by Country, Through 2029
Table 272 : European Market for PCR POC Diagnostics in STIs, Through 2029
Table 273 : European Market for PCR POC Diagnostics in STIs, by Country, Through 2029
Table 274 : Asia-Pacific Market for PCR POC Diagnostics in STIs, Through 2029
Table 275 : Asia-Pacific Market for PCR POC Diagnostics in STIs, by Country, Through 2029
Table 276 : RoW Market for PCR POC Diagnostics in STIs, Through 2029
Table 277 : Global Market for PCR for POC Diagnostics, by Region, Through 2029
Table 278 : North American Market for PCR POC Diagnostics, by Product Type, Through 2029
Table 279 : North American Market for PCR POC Diagnostics, by Country, Through 2029
Table 280 : Latin American Market for PCR POC Diagnostics, by Product Type, Through 2029
Table 281 : Latin American Market for PCR POC Diagnostics, by Country, Through 2029
Table 282 : European Market for PCR POC Diagnostics, by Product Type, Through 2029
Table 283 : European Market for PCR POC Diagnostics, by Country, Through 2029
Table 284 : Asia-Pacific Market for PCR POC Diagnostics, by Product Type, Through 2029
Table 285 : Asia-Pacific Market for PCR POC Diagnostics, by Country, Through 2029
Table 286 : RoW Market for PCR POC Diagnostics, by Product Type, Through 2029
Table 287 : Global Market for Rare Disease Diagnostics, by Disease Class, Through 2029
Table 288 : Rare Disease Prevalence Definitions
Table 289 : Statistics for Rare Diseases
Table 290 : Most Prevalent Rare Diseases
Table 291 : Examples of Genomic Biomarkers
Table 292 : Rare Disease Diagnostics Key Genetic Analysis Platforms
Table 293 : Genome Coverage of PCR, Microarray and NGS Technology Platforms
Table 294 : NGS vs. qPCR vs. Microarrays: A Detailed Comparison
Table 295 : Multiple Paths to Market for Rare Disease Tests
Table 296 : Bioinformatic Resources for Rare Disease Research and Genetic Information
Table 297 : Impact of Large-Scale Initiatives on the Rare Disease Diagnostic Industry
Table 298 : Key Rare Disease Initiatives
Table 299 : Population Sequencing Projects
Table 300 : Pathways for Accelerated Approval of Rare Disease Therapies, by Country/Region
Table 301 : Genetic Modification Approaches for Rare Diseases
Table 302 : Distinct Features of the Genetic Modification Approaches
Table 303 : Comparison of Clinical Genomic Testing Methods for Analysis of Genomic Variants
Table 304 : Driving Forces and Their Impact on Rare Disease Diagnostic Market Growth
Table 305 : Rare Disease Diagnostics Artificial Intelligence Industry
Table 306 : Global Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 307 : NGS Applications in Rare Diseases
Table 308 : Key Forces Driving Growth in Clinical NGS and Their Implications
Table 309 : Main Ingredients for Polymerase Chain Reaction
Table 310 : Polymerase Chain Reaction Process Steps
Table 311 : Sanger Sequencing Summary
Table 312 : Sanger Sequencing Improvements
Table 313 : Molecular Genetic Testing Methods
Table 314 : Cytogenetics Testing Methods
Table 315 : Biochemical Genetics Methods
Table 316 : Global Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
Table 317 : Single-Gene Disorders
Table 318 : Comparison of Techniques Employed to Study Rare Genetic Diseases
Table 319 : Comparison of Genomic Methods for Rare Disease Diagnosis
Table 320 : Global Market for Rare Disease Diagnostics, by Disease Class, Through 2029
Table 321 : Rare Cancer-Focused Initiatives and Consortia
Table 322 : Selected Rare Cancer Prevalence, 2022
Table 323 : Global Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 324 : Preventive Genetic Screening Tests
Table 325 : Global Market for Rare Disease Diagnostics, by Region, Through 2029
Table 326 : NIH Funding, 2018-FY2025
Table 327 : Key FDA Programs to Support Rare Disease Research
Table 328 : North American Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 329 : North American Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
Table 330 : North American Market for Rare Disease Diagnostics, by Disease Class, Through 2029
Table 331 : North American Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 332 : North American Market for Rare Disease Diagnostics, by Country, Through 2029
Table 333 : U.S. Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 334 : U.S. Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 335 : Canadian Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 336 : Canadian Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 337 : Mexican Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 338 : Mexican Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 339 : Overview of Actions Taken by the EU to Address Challenges in the Field of Rare Diseases Diagnosis
Table 340 : European Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 341 : European Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
Table 342 : European Market for Rare Disease Diagnostics, by Disease Class, Through 2029
Table 343 : European Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 344 : European Market for Rare Disease Diagnostics, by Country, Through 2029
Table 345 : German Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 346 : German Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 347 : U.K. Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 348 : U.K. Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 349 : French Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 350 : French Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 351 : Italian Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 352 : Italian Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 353 : Spanish Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 354 : Spanish Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 355 : Rest of European Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 356 : Rest of European Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 357 : Asia-Pacific Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 358 : Asia-Pacific Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
Table 359 : Asia-Pacific Market for Rare Disease Diagnostics, by Disease Class, Through 2029
Table 360 : Asia-Pacific Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 361 : Asia-Pacific Market for Rare Disease Diagnostics, by Country, Through 2029
Table 362 : Chinese Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 363 : Chinese Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 364 : Japanese Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 365 : Japanese Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 366 : Australian Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 367 : Australian Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 368 : South Korean Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 369 : South Korean Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 370 : Rest of Asia-Pacific Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 371 : Rest of Asia-Pacific Market for Rare Disease Diagnostics, by Test Purpose, Through 2029
Table 372 : RoW Market for Rare Disease Diagnostics, by Analysis Platform, Through 2029
Table 373 : RoW Market for Rare Disease Diagnostics, by Analysis Target, Through 2029
Table 374 : RoW Market for Rare Disease Diagnostics, by Disease Class, Through 2029
Table 375 : RoW Market for Rare Disease Diagnostics, by Test Purpose, Through 2029

List of Figures

Figure 1 : Market Dynamics of AI in Clinical and Molecular Diagnostics
Figure 2 : Global Market Shares of AI in Clinical and Molecular Diagnostics, by Type, 2023
Figure 3 : Global Market Shares of AI in Molecular Diagnostics, by Application, 2023
Figure 4 : Global Deaths from Cancer, 2015 and 2030
Figure 5 : Global Market Shares of AI in Molecular Diagnostics, by Product Type, 2023
Figure 6 : Global Market Shares of AI in Clinical Diagnostics, by Test, 2023
Figure 7 : Global Market Shares of AI in Clinical Diagnostics, by Product, 2023
Figure 8 : Global Market Shares of AI in Clinical and Molecular Diagnostics, by Component, 2023
Figure 9 : Global Market Shares of AI in Clinical and Molecular Diagnostics, by Region, 2023
Figure 10 : North American Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023
Figure 11 : European Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023
Figure 12 : Asia-Pacific Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023
Figure 13 : RoW Market Shares of AI in Clinical and Molecular Diagnostics, by Sub-Region, 2023
Figure 14 : Timeline of FDA Guidance Release for Companion Diagnostics (CDx), as of 2023
Figure 15 : Market Dynamics of Companion Diagnostics
Figure 16 : Share of Global Cancer Incidence for Both Sexes, by Region, 2022
Figure 17 : Companion Diagnostics: Growing Share in Total New Molecular Entities (NMEs), 2019-2022
Figure 18 : Emerging Trends/Technologies in the Companion Diagnostics Market
Figure 19 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, 2021-2029
Figure 20 : Market Dynamics of Drugs and Diagnostics for Hematological Disorders
Figure 21 : Incidence of Blood Cancer Types, by Region, 2022
Figure 22 : Global Market Shares of Drugs and Diagnostics for Hematological Disorders, by Segment, 2023
Figure 23 : Global Market Shares of Diagnostics for Hematological Disorders, by Product Type, 2023
Figure 24 : Global Market Shares of Diagnostics for Hematological Disorders, by End User, 2023
Figure 25 : Global Market Shares of Hematology Drugs, by Drug Type, 2023
Figure 26 : North American Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
Figure 27 : New Cases of Leukemia, Lymphoma and Myeloma in U.S., 2023
Figure 28 : European Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
Figure 29 : Asia-Pacific Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
Figure 30 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
Figure 31 : In Vitro Diagnostics (IVD) Quality Controls Global Market: Market Dynamics
Figure 32 : Distribution of Elderly Population (Aged 65 and above), by Top Countries, 2022
Figure 33 : Comparison Between Third-Party Controls and Original Equipment Manufacturer Controls
Figure 34 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Test Type 2023
Figure 35 : Global Market Shares of In Vitro Diagnostics Quality Control, by Type of Manufacturer 2023
Figure 36 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Type of Product and Service, 2023
Figure 37 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Type of Quality Control Product, 2023
Figure 38 : Global Market Shares of In Vitro Diagnostics Quality Controls, by End-user, 2023
Figure 39 : Global Market Shares of In Vitro Diagnostics Quality Controls, by Region, 2023
Figure 40 : North American Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
Figure 41 : North American Market Shares of In Vitro Diagnostics Quality Controls, by Type of Manufacturer, 2023
Figure 42 : North American Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023
Figure 43 : North American Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023
Figure 44 : North American Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023
Figure 45 : North American Market Shares of In Vitro Diagnostics Quality Controls, by Country, 2023
Figure 46 : European Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
Figure 47 : European Market Shares of In Vitro Diagnostics Quality Controls, by Type of Manufacturer, 2023
Figure 48 : European Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023
Figure 49 : European Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023
Figure 50 : European Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023
Figure 51 : European Market Shares of In Vitro Diagnostics Quality Controls, by Country, 2023
Figure 52 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
Figure 53 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Type of Manufacturer, 2023
Figure 54 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023
Figure 55 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023
Figure 56 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023
Figure 57 : Asia-Pacific Market Shares of In Vitro Diagnostics Quality Controls, by Country, 2023
Figure 58 : Rest of World Market Shares of In Vitro Diagnostics Quality Controls, by Test Type, 2023
Figure 59 : Rest of World Market Shares of In Vitro Diagnostic Quality Controls, by Type of Manufacturer, 2023
Figure 60 : Rest of World Market Shares of In Vitro Diagnostics Quality Controls, by Product and Service, 2023
Figure 61 : Rest of World Market Shares of In Vitro Diagnostics Quality Control Products, by Type of Product, 2023
Figure 62 : Rest of World Market Shares of In Vitro Diagnostics Quality Controls, by End User, 2023
Figure 63 : Rest of the World Market Shares of In Vitro Diagnostics Quality Controls, by Country/Sub-Region, 2023
Figure 64 : Global Market Dynamics of Point-of-Care Diagnostics
Figure 65 : Malaria-Endemic Countries, 2022
Figure 66 : Top 10 Common Chronic Conditions in Adults 65+, U.S., 2024
Figure 67 : Annual Investment in STI Research Needs of People in Low- and Middle-Income Countries, 2018-2022
Figure 68 : Global Market Shares of Point-of-Care Diagnostics, by Test Type, 2023
Figure 69 : Share of New Cancer Cases Globally, by Region, 2022
Figure 70 : Share of Cancer Mortality Cases Globally, by Region, 2022
Figure 71 : Global Market Shares of Point-of-Care Diagnostics, by Product, 2023
Figure 72 : Global Market Shares of Point-of-Care Diagnostics, by End User, 2023
Figure 73 : COVID-19 Diagnostic Possibilities, Sampling, and Turnaround Time
Figure 74 : Global Market Shares of Point-of-Care Diagnostics, by Region, 2023
Figure 75 : North American Market Shares in Point-of-Care Diagnostics, by Country, 2023
Figure 76 : Limitations of Using POC Devices in India
Figure 77 : Global Market Shares of Polymerase Chain Reaction for Point-of-Care Diagnostics, by Product Type, 2023
Figure 78 : Polymerase Chain Reaction for Point of Care Diagnostics: Market Dynamics
Figure 79 : Emerging Trends and Technologies in PCR for POC Diagnostics
Figure 80 : Global Market Shares of Rare Disease Diagnostics, by Disease Class, 2023
Figure 81 : Market Dynamics of Rare Disease Diagnostics
Figure 82 : FDA Approval for Orphan Drugs, 2020-2023
Figure 83 : Cost Per Genome, November 2017-May 2022
Figure 84 : Phase-Out Plan of FDA's Enforcement Discretion Approach
Figure 85 : Global Market Shares of Rare Disease Diagnostics, by Analysis Platform, 2023
Figure 86 : Global Market Shares of Rare Disease Diagnostics, by Analysis Target, 2023
Figure 87 : Global Market Shares of Rare Disease Diagnostics, by Disease Class, 2023
Figure 88 : Global Market Shares of Rare Disease Diagnostics, by Test Purpose, 2023
Figure 89 : Global Market for Rare Disease Diagnostics, by Region, 2021-2029
Figure 90 : Global Market Shares of Rare Disease Diagnostics, by Region, 2023
Figure 91 : NIH Funding for Rare Diseases, 2018-2025E
Figure 92 : North American Market Shares of Rare Disease Diagnostics, by Country, 2023
Figure 93 : European Market Shares of Rare Disease Diagnostics, by Country, 2023
Figure 94 : Asia-Pacific Market Shares of Rare Disease Diagnostics, by Country, 2023

2024 Diagnostics Research Review

Description

Table of Contents

List of Tables

Table of Contents

Chapter 1 Foreword

Chapter 2 AI in Clinical and Molecular Diagnostics Market(BIO261A)

Chapter 3 Companion Diagnostics: Technologies and Markets ( BIO077F)

Chapter 4 Drugs and Diagnostics for Hematological Disorders: Global Markets (PHM116C)

Chapter 5 In Vitro Diagnostics (IVD) Quality Controls: Global Market( BIO233B)

Chapter 6 Point-of-Care Diagnostics: Technologies and Global Markets ( HLC043H)

Chapter 7 Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics (BIO157C)

Chapter 8 Rare Disease Diagnostics: Technologies and Global Markets (PHM227B)

Chapter 9 Appendix

List of Tables

List of Figures